Narrow search
Showing 1 - 10 of 15,600
Cover Image
Pharmaceutical Antitrust Enforcement in the United States and Chile
Carrier, Michael A.; Araya, Fernando - 2021
Consumers suffer from high drug prices, which stem in large part from pharmaceutical companies’ anticompetitive games. This essay discusses the crucial role antitrust enforcement agencies can play in addressing pay-for-delay settlements and product hopping and draws lessons from this...
Persistent link: https://www.econbiz.de/10013215870
Cover Image
United States Special 301 : a deeply flawed tool for IPR regulation?
Qureshi, Asif H. - In: Journal of world trade : law, economic policy, public policy 55 (2021) 3, pp. 499-520
Persistent link: https://www.econbiz.de/10012609439
Cover Image
Antitrust in the Pharmaceutical Sector : An Overview of U.S. Case Law
Carrier, Michael A. - 2018
Persistent link: https://www.econbiz.de/10014110600
Cover Image
An Ounce of Prevention or a Pound of Cure? Short- and Long-Run Effects of Pharmaceutical Patents on U.S. Health Care Expenditures
Johnson, Hilary S.; Johnson, Daniel K. N. - 2014
driving the costs of pharmaceuticals, and develop a structured vector autoregressive (SVAR) model to measure the social rate …-run prices in pharmaceuticals themselves, but with lower long-run prices in the aggregate medical sector which includes … pharmaceuticals as a component part. Further, the TRIPS Agreement and Hatch-Waxman Act to enable generic competition have both been …
Persistent link: https://www.econbiz.de/10014209235
Cover Image
The US Supreme Court Issues First Ruling on Antitrust Legality of Reverse-Payment Drug Patent Settlements (Actavis)
Carrier, Michael A. - 2014
This short article summarizes FTC v. Actavis, the first case in which the Supreme Court analyzed the antitrust legality of agreements by which brand-name drug companies pay generics to settle patent litigation and delay entering the market. It concludes that the ruling must be counted as a win...
Persistent link: https://www.econbiz.de/10014155650
Cover Image
Evaluating the US pharmaceutical patent policy
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
Cover Image
Collusion in the US generic drug industry
Clark, Robert; Fabiilli, Christopher Anthony; Lasio, Laura - 2021
We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...
Persistent link: https://www.econbiz.de/10012670921
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - 2010
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10014191301
Cover Image
Evaluating the US Pharmaceutical Patent Policy
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2022
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10013309494
Cover Image
Bargaining and International Reference Pricing in the Pharmaceutical Industry
Dubois, Pierre; Gandhi, Ashvin; Vasserman, Shoshana - National Bureau of Economic Research - 2022
The United States spends twice as much per person on pharmaceuticals as European countries, in large part because … reference countries. We estimate a structural model of demand and supply for pharmaceuticals in the US and reference countries …
Persistent link: https://www.econbiz.de/10013210081